ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

• Published in: Cephalalgia Vol. 38; no. 6; pp. 1026 - 1037
• Main Authors: Dodick, David W, Ashina, Messoud, Brandes, Jan Lewis, Kudrow, David, Lanteri-Minet, Michel, Osipova, Vera, Palmer, Kerry, Picard, Hernan, Mikol, Daniel D, Lenz, Robert A
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2018
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Calcitonin Gene-Related Peptide - antagonists & inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Treatment Outcome; Young Adult; calcitonin gene-related peptide; Erenumab; migraine; safety; efficacy

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. Methods In this randomized, double-blind, placebo-controlled,...